CN: 32-1845/R
ISSN: 2095-6975
Cite this paper:
0
ZHOU Xiao-Hang, ZHANG Ai-Hua, WANG Liang, TAN Yun-Long, GUAN Yu, HAN Ying, SUN Hui, WANG Xi-Jun. Novel chinmedomics strategy for discovering effective constituents from ShenQiWan acting on ShenYangXu syndrome[J]. Chinese Journal of Natural Medicines, 2016, 14(8): 561-581

Novel chinmedomics strategy for discovering effective constituents from ShenQiWan acting on ShenYangXu syndrome

ZHOU Xiao-Hang, ZHANG Ai-Hua, WANG Liang, TAN Yun-Long, GUAN Yu, HAN Ying, SUN Hui, WANG Xi-Jun
National TCM Key Laboratory of Serum Pharmacochemistry, Sino-US Chinmedomics Technology Cooperation Center, Research Center of Chinmedomics(State Administration of TCM), Laboratory of Metabolomics, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Harbin 150040, China
Abstract:
Elucidation of the efficacy of traditional Chinese medicine (TCM) is of importance for scientists of modern medicine to understand the value of TCM clinical experience, and it is necessary to have a biological language to scientifically describe the efficacy of TCM. With this background,Chinmedomics has been proposed by our team, which includes integrating serum pharmacochemistry and metabolomics technology, defining theory and research methods for expressing the efficacy of TCMs based on the biomarkers discovery of TCM syndrome and elucidating the efficacy of TCM formulae, discovering effective constituents, and finally elucidating the scientific value of TCM. In the present study, the innovative chinmedomics strategy was conducted to evaluate the therapeutic effects of ShenQiWan (SQW) acting on ShenYangXu (kidney-yang deficiency syndrome, KYDS). We analyzed the urine metabolic trajectory between the model and control groups, and identified the biomarkers by the multivariate analysis. We found that SQW caused significant restoration of abnormal metabolism of KYDs. Using the method of metabolomics, 17 potential urine biomarkers were analyzed through 4 repeated tests in our serial studies on SQW and KYDS. Under the premise of therapeutic efficacy, a total of 56 peaks were tentatively characterized in vivo by the use of serum pharmacochemistry. Correlation analysis between marker metabolites and in vivo constituents of SQW showed that 28 compositions had a close relationship with urine biomarkers of therapeutic effects, whichmight play a key role in the therapeutic effect of SQW. These compounds were imported into an online database to predict their targets. Twenty-three important potential targets were identified, which were related to the metabolism of steroid hormone, tryptophan utilization, and thyroid hormone. In conclusion, chinmedomics is a useful strategy for discovery of potentially effective constituents from complex TCM formulae.
Key words:    Chinmedomics    ShenQiWan    ShenYangXu syndrome    Metabolomics    Serum pharmacochemistry   
Received: 2016-02-26   Revised:
Tools
PDF (27399 KB) Free
Print this page
Email this article to others
Authors
Articles by ZHOU Xiao-Hang
Articles by ZHANG Ai-Hua
Articles by WANG Liang
Articles by TAN Yun-Long
Articles by GUAN Yu
Articles by HAN Ying
Articles by SUN Hui
Articles by WANG Xi-Jun
References:
[1] Wang X, Zhang A, Sun H. Future perspectives of Chinese medical formulae:chinmedomics as an effector[J]. OMICS, 2012, 16(7-8):414-421.
[2] Wang X, Zhang A, Zhou X, et al. An integrated chinmedomics strategy for discovery of effective constituents from traditional herbal medicine[J]. Sci Rep, 2016, 6:18997.
[3] Zhang A, Sun H, Wang P, et al. Modern analytical techniques in metabolomics analysis[J]. Analyst, 2012, 137(2):293-300.
[4] Zhang A, Wang H, Sun H, et al. Metabolomics strategy reveals therapeutical assessment of limonin on nonbacterial prostatitis[J]. Food Funct, 2015, 6(11):3540-3549.
[5] Wang X, Zhang A, Han Y, et al. Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease[J]. Mol Cell Proteomics, 2012, 11(8):370-380.
[6] Zhang A, Sun H, Han Y, et al. Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach[J]. Analyst, 2012, 137(18):4200-4208.
[7] Pan Z, Fang Z, Lu W, et al. Osthole, a Coumadin analog from Cnidium monnieri (L.) Cusson, stimulates corticosterone secretion by increasing steroidogenic enzyme expression in mouse Y1 adrenocortical tumor cells[J]. J Ethnopharmacol, 2015, 175:456-462
[8] Gong Y, Liu L, He X, et al. The Th17/Treg immune balance in ulcerative colitis patients with two different chinese syndromes:dampness-heat in large intestine and spleen and kidney yang deficiency syndrome[J]. Evid Based Complement Alternat Med, 2015, 2015:264317.
[9] Tan Y, Liu X, Lu C, et al. Metabolic profiling reveals therapeutic biomarkers of processed Aconitum carmichaeli Debx in treating hydrocortisone induced kidney-yang deficiency syndrome rats[J]. J Ethnopharmacol, 2014, 152(3):585-593.
[10] Zhao L, Wu H, Qiu M, et al. Metabolic Signatures of kidney yang deficiency syndrome and protective effects of two herbal extracts in rats using GC/TOF MS[J]. Evid Based Complement Alternat Med, 2013, 2013:540957.
[11] Kuang AK, Chen JL, Chen MD, et al. Effects of Yang-Restoring and Yin-Nourishing herbs on serum TRH, T3 and T4 levels in experimental hyperthyroid and hypothyroid rats[J]. Chin J Integr Tradit West Med, 1987, 7(11):674-647
[12] Chen Y, Shen ZY, Chen WH. Comparative study of kidney-tonifying recipes and spleen-invigorating recipe on regulating pattern of the expression of T lymphocyte apoptosis signaling-related genes in corticosterone-treated rats[J]. J Integr Med, 2004, 2(5):346-349
[13] Zhang A, Liu Q, Zhao H, et al. Phenotypic characterization of nanshi oral liquid alters metabolic signatures during disease prevention[J]. Sci Rep, 2016, 6:19333.
[14] Wang X, Sun H, Zhang A, et al. Potential role of metabolomics apporoaches in the area of traditional Chinese medicine:as pillars of the bridge between Chinese and Western medicine[J]. J Pharm Biomed Anal, 2012, 55(5):859-868.
[15] Wang X, Zhang B. Elucidation of compatibilityprinciple and scientific value of Chinese medical formulae based on pharmacometabolomics[J]. China J Chin Mater Med, 2010, 35(10):1346-1348
[16] Cao H, Zhang A, Sun H, et al. Metabolomics-proteomics profiles delineate metabolic changes in kidney fibrosis disease[J]. Proteomics, 2015, 15(21):3699-3710
[17] Poisson LM, Suhail H, Singh J, et al. Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis[J]. J Biol Chem, 2015, 290(52):30697-30712
[18] Llorach-Asunción R, Jauregui O, Urpi-Sarda M, et al. Methodological aspects for metabolome visualization and characterization A metabolomic evaluation of the 24 h evolution of human urine after cocoa powder consumption[J]. J Pharm Biomed Anal, 2012, 51(2):373-381
[19] Wang P, Sun H, Lv HT, et al. Thyroxine and reserpine-induced changes in metabolic profiles of rat urine and the therapeutic effect of Liu Wei Di Huang Wan detected by UPLC-HDMS[J]. J Pharm Biomed Anal, 2010, 53(3):631-645
[20] Pawlak K, Brzosko S, Mysliwiec M, et al. Kynurenine, quinolinic acid-The new factors linked to carotid atherosclerosis in patients with end-stage renal disease[J]. Atherosclerosis, 2009, 204(2):561-566.
[21] Zhao YY, Li HT, Feng YL, et al. Urinary metabonomic study of the surface layer of Poria cocos as an effective treatment for chronic renal injury in rats[J]. J Ethnopharmacol, 2013, 148(2):403-410.
[22] Pawlak D, Tankiewicz A, Buczko W. Kynurenine and its metabolites in the rat with experimental renal insufficiency[J]. J Physiol Pharmacol, 2001, 52(4 Pt 2):755-766.
[23] Watanabe H, Miyamoto Y, Otagiri M, et al. Update on the pharmacokinetics and redox properties of protein-bound uremic toxins[J]. J Pharm Sci, 2011, 100(9):3682-3695
[24] Tamijani SM, Karimi B, Amini E, et al. Thyroid hormones:Possible roles in epilepsy pathology[J]. Seizure, 2015, 31:155-164.
[25] Eisenhofer G, Rundquist B, Aneman A, et al. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines[J]. J Clin Endocrinol Metab, 1995, 80(10):3009-3017
[26] Erem C, Kocak M, Cinel A, et al. Dopamine-secreting adrenal ganglioneuroma presenting with paroxysmal hypertension attacks[J]. Saudi Med J, 2008, 29(1):122-125.
[27] Erem C, Kocak M, Cinel A, et al.. Dopamine-secreting adrenal ganglioneuroma presenting with paroxysmal hypertension attacks[J]. Saudi Med J, 2008, 29(1):122-125
[28] Mokarram P, Alizadeh J, Razban V. Interconnection of estrogen/testosterone metabolism and mevalonate pathway in breast and prostate cancers[J]. Curr Mol Pharmacol, 2016[Epub ahead of print]
[29] Barrios C, Spector T, Menni C. Blood, urine and faecal metabolite profiles in the study of adult renal disease[J]. Arch Biochem Biophys, 2016, 589:81-92.
[30] Shlipak MG, Matsushita K, Ärnlöv J, et al. Prognosis, Consortium. Cystatin C versus creatinine in determining risk based on kidney function[J]. N Engl J Med, 2013, 369(10):932-943.
[31] Terrill JR, Grounds MD, Arthur PG. Taurine deficiency, synthesis and transport in the mdx mouse model for Duchenne Muscular Dystrophy[J]. Int J Biochem Cell Biol, 2015, 66:141-148.
[32] Roman-Garcia P, Quiros-Gonzalez I, Mottram L, et al. Vitamin B12-dependent taurine synthesis regulates growth and bone mass[J]. J Clin Invest, 2014, 124(7):2988-3002
[33] Wang YJ, Huang SL, Feng Y, et al. Emodin, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and exerts anti-diabetic effect in ob/ob mice[J]. Acta Pharmacol Sin, 2012, 33(9):1195-1203.